StockMarketWire.com - ANGLE said its Parsortix system is the subject of a further peer-reviewed publication in the journal Oncotarget.

It said this details work undertaken by Prof. Robert Zeillinger's Molecular Oncology Group at the Medical University of Vienna (Vienna).

Zeillinger is a key opinion leader in the field of liquid biopsies use in oncology.

Zeillinger's group developed and tested protocols to allow the molecular characterisation of the circulating tumour cells (CTCs) and residual blood cells harvested by the Parsortix system without the need to separate out the CTCs.

A statement by ANGLE said: 'This was only possible because the Parsortix system provides high purity cells with very efficient removal of white blood cells.

' With alternative approaches for CTC enrichment such as density gradient centrifugation, this has not been possible, as high levels of contaminating white blood cells remain with the CTCs captured.'

Zeillinger said: 'In the study we have demonstrated that ANGLE's Parsortix system addresses key limitations of other approaches for CTC liquid biopsy through the combination of its sensitivity in isolating circulating cancer cells in blood and the high purity of the harvested cells enabling their direct molecular analysis.'

ANGLE founder and chief executive Andrew Newland said: 'This published study further demonstrates that the Parsortix system outperforms other approaches for harvesting circulating tumour cells from the blood of cancer patients in the fast emerging liquid biopsy market.

'The capability to harvest cancer cells with high purity to allow direct molecular analysis of the cells strongly differentiates our system, which should facilitate adoption in clinical practice.'


At 9:20am: [LON:AGL] Angle PLC share price was +1.5p at 45p



Story provided by StockMarketWire.com